Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 213

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 213
---
 Plans:

SUMMARY OF OPTION ACTIVITY

|                             |     | Number     
 of options |          |   |     | Weighted- average exercise 
 price                      |      |     | Weighted- average remaining contractual term 
 (in years)                                   |      |     | Aggregate intrinsic 
 value               |         |
|:----------------------------|:----|:-----------|---------:|:--|:----|:---------------------------|-----:|:----|:---------------------------------------------|-----:|:----|:--------------------|--------:|
| Outstanding at December 31, 
 2023                        |     |            |  683,695 |   |     | $                          | 3.99 |     |                                              |  2.9 |     | $                   | 158,332 |
| Granted                     |     |            |        — |   |     |                            |    — |     |                                              |    — |     |                     |       — |
| Exercised                   |     |            | (208,031 | ) |     |                            | 1.16 |     |                                              |    — |     |                     |       — |
| Forfeited                   |     |            | (171,539 | ) |     |                            | 2.16 |     |                                              |    — |     |                     |       — |
| Outstanding at December     
 31, 2024                    |     |            |  304,125 |   |     | $                          | 6.95 |     |                                              | 4.20 |     | $                   |       — |
| Vested and exercisable      
 at December 31, 2024        |     |            |  304,125 |   |     | $                          | 6.95 |     |                                              | 4.20 |     | $                   |       — |

As of December 31, 2024, there was nounrecognized compensation cost related to non-vested stock options.

During the year ended December 31, 2024, 208,031options were exercised at an exercise price of $ 1.155, of which 143,183options were from a cashless exercise, and 137,854options were forfeited due to a cashless exercise.

| F-14 |

Restricted Stock Awards

The following table summarizes restricted stock award activity under the 2014 and 2024 Plan:

SUMMARY OF RESTRICTED STOCK AWARD

|                              |